fiercepharma
Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption. However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care. Accenture research finds that leaders in New Science are investing 6-7x more in digital, data and genomics compared to their peers.
Watch Now
Life science companies face major obstacles to continue operations and profitability. Examples include patent expirations, low research and development productivity, increased competition, decreased margins, non-optimized processes and mounting compliance pressure.
Watch Now
Abcam plc
What makes a good potential target for drug discovery? Listen in as Dr. Elizabeth Glennon, of King's College London, discusses how the disruption of axonal transports early on within Alzheimer's Disease provides excellent targets for drug discovery. How the disruption of axonal transport contributes to the development of Alzheimer's disease. Mechanisms of axonal transport of the Alzheimer's amyloid precursor protein, and how these are altered in the disease.
Watch Now
questexweb
Biopharmaceutical companies are increasingly challenged to create a drug pricing strategy that both rewards value and innovation, and promotes affordability and access. During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues, including:
Watch Now